| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acceptability of less than perfect health states in rheumatoid arthritis: the patients’ perspective
|
Péntek, Márta
|
|
2014
|
15 |
supplement-1 |
p. 73-82
|
artikel
|
| 2 |
Biological and biosimilar therapies in inflammatory conditions: challenges for the Central and Eastern European countries
|
Gulácsi, László
|
|
2014
|
15 |
supplement-1 |
p. 1-4
|
artikel
|
| 3 |
Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries
|
Péntek, Márta
|
|
2014
|
15 |
supplement-1 |
p. 35-43
|
artikel
|
| 4 |
Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
|
Brodszky, Valentin
|
|
2014
|
15 |
supplement-1 |
p. 65-71
|
artikel
|
| 5 |
Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010
|
Boncz, Imre
|
|
2014
|
15 |
supplement-1 |
p. 137-141
|
artikel
|
| 6 |
Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis
|
Baji, Petra
|
|
2014
|
15 |
supplement-1 |
p. 45-52
|
artikel
|
| 7 |
Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres
|
Balogh, Orsolya
|
|
2014
|
15 |
supplement-1 |
p. 101-109
|
artikel
|
| 8 |
Economic burden of long-term care of rheumatoid arthritis patients in Hungary
|
Horváth, Zoltán
|
|
2014
|
15 |
supplement-1 |
p. 131-135
|
artikel
|
| 9 |
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
|
Baji, Petra
|
|
2014
|
15 |
supplement-1 |
p. 53-64
|
artikel
|
| 10 |
Erratum to: Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
|
Mandel, Michael D.
|
|
2014
|
15 |
supplement-1 |
p. 129
|
artikel
|
| 11 |
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary
|
Herédi, Emese
|
|
2014
|
15 |
supplement-1 |
p. 111-119
|
artikel
|
| 12 |
Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria
|
Gulácsi, László
|
|
2014
|
15 |
supplement-1 |
p. 13-25
|
artikel
|
| 13 |
Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis
|
Gulyas, Katalin
|
|
2014
|
15 |
supplement-1 |
p. 93-100
|
artikel
|
| 14 |
Statistical and regulatory considerations in assessments of interchangeability of biological drug products
|
Tóthfalusi, Lászlo
|
|
2014
|
15 |
supplement-1 |
p. 5-11
|
artikel
|
| 15 |
Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists
|
Péntek, Márta
|
|
2014
|
15 |
supplement-1 |
p. 83-92
|
artikel
|
| 16 |
Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries
|
Gulácsi, László
|
|
2014
|
15 |
supplement-1 |
p. 27-34
|
artikel
|
| 17 |
Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
|
Michael, Mandel D.
|
|
2014
|
15 |
supplement-1 |
p. 121-128
|
artikel
|
Tijdschrift beschrijving